A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

707

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Umeclidinium/vilanterol
DRUG: Fluticasone propionate/salmeterol
DRUG: Placebo

Sponsor

GlaxoSmithKline